These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 29321258)

  • 1. Functional variants in the
    Hui KY; Fernandez-Hernandez H; Hu J; Schaffner A; Pankratz N; Hsu NY; Chuang LS; Carmi S; Villaverde N; Li X; Rivas M; Levine AP; Bao X; Labrias PR; Haritunians T; Ruane D; Gettler K; Chen E; Li D; Schiff ER; Pontikos N; Barzilai N; Brant SR; Bressman S; Cheifetz AS; Clark LN; Daly MJ; Desnick RJ; Duerr RH; Katz S; Lencz T; Myers RH; Ostrer H; Ozelius L; Payami H; Peter Y; Rioux JD; Segal AW; Scott WK; Silverberg MS; Vance JM; Ubarretxena-Belandia I; Foroud T; Atzmon G; Pe'er I; Ioannou Y; McGovern DPB; Yue Z; Schadt EE; Cho JH; Peter I
    Sci Transl Med; 2018 Jan; 10(423):. PubMed ID: 29321258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LRRK2 N551K and R1398H variants are protective in Malays and Chinese in Malaysia: A case-control association study for Parkinson's disease.
    Gopalai AA; Lim JL; Li HH; Zhao Y; Lim TT; Eow GB; Puvanarajah S; Viswanathan S; Norlinah MI; Abdul Aziz Z; Lim SK; Tan CT; Tan AH; Lim SY; Tan EK; Ahmad Annuar A
    Mol Genet Genomic Med; 2019 Nov; 7(11):e604. PubMed ID: 31487119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coding and Noncoding Variation in LRRK2 and Parkinson's Disease Risk.
    Lake J; Reed X; Langston RG; Nalls MA; Gan-Or Z; Cookson MR; Singleton AB; Blauwendraat C; Leonard HL;
    Mov Disord; 2022 Jan; 37(1):95-105. PubMed ID: 34542912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Targets from LRRK2 Rescue Phenotypes.
    Toh J; Chua LL; Ho P; Sandanaraj E; Tang C; Wang H; Tan EK
    Cells; 2021 Jan; 10(1):. PubMed ID: 33466414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry.
    Lee AJ; Wang Y; Alcalay RN; Mejia-Santana H; Saunders-Pullman R; Bressman S; Corvol JC; Brice A; Lesage S; Mangone G; Tolosa E; Pont-Sunyer C; Vilas D; Schüle B; Kausar F; Foroud T; Berg D; Brockmann K; Goldwurm S; Siri C; Asselta R; Ruiz-Martinez J; Mondragón E; Marras C; Ghate T; Giladi N; Mirelman A; Marder K;
    Mov Disord; 2017 Oct; 32(10):1432-1438. PubMed ID: 28639421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The landscape of rare genetic variation associated with inflammatory bowel disease and Parkinson's disease comorbidity.
    Kars ME; Wu Y; Stenson PD; Cooper DN; Burisch J; Peter I; Itan Y
    Genome Med; 2024 May; 16(1):66. PubMed ID: 38741190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study.
    Ross OA; Soto-Ortolaza AI; Heckman MG; Aasly JO; Abahuni N; Annesi G; Bacon JA; Bardien S; Bozi M; Brice A; Brighina L; Van Broeckhoven C; Carr J; Chartier-Harlin MC; Dardiotis E; Dickson DW; Diehl NN; Elbaz A; Ferrarese C; Ferraris A; Fiske B; Gibson JM; Gibson R; Hadjigeorgiou GM; Hattori N; Ioannidis JP; Jasinska-Myga B; Jeon BS; Kim YJ; Klein C; Kruger R; Kyratzi E; Lesage S; Lin CH; Lynch T; Maraganore DM; Mellick GD; Mutez E; Nilsson C; Opala G; Park SS; Puschmann A; Quattrone A; Sharma M; Silburn PA; Sohn YH; Stefanis L; Tadic V; Theuns J; Tomiyama H; Uitti RJ; Valente EM; van de Loo S; Vassilatis DK; Vilariño-Güell C; White LR; Wirdefeldt K; Wszolek ZK; Wu RM; Farrer MJ;
    Lancet Neurol; 2011 Oct; 10(10):898-908. PubMed ID: 21885347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect?
    Orr-Urtreger A; Shifrin C; Rozovski U; Rosner S; Bercovich D; Gurevich T; Yagev-More H; Bar-Shira A; Giladi N
    Neurology; 2007 Oct; 69(16):1595-602. PubMed ID: 17938369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crohn's and Parkinson's Disease-Associated LRRK2 Mutations Alter Type II Interferon Responses in Human CD14
    Ikezu T; Koro L; Wolozin B; Farraye FA; Strongosky AJ; Wszolek ZK
    J Neuroimmune Pharmacol; 2020 Dec; 15(4):794-800. PubMed ID: 32180132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants.
    Heckman MG; Elbaz A; Soto-Ortolaza AI; Serie DJ; Aasly JO; Annesi G; Auburger G; Bacon JA; Boczarska-Jedynak M; Bozi M; Brighina L; Chartier-Harlin MC; Dardiotis E; Destée A; Ferrarese C; Ferraris A; Fiske B; Gispert S; Hadjigeorgiou GM; Hattori N; Ioannidis JP; Jasinska-Myga B; Jeon BS; Kim YJ; Klein C; Kruger R; Kyratzi E; Lin CH; Lohmann K; Loriot MA; Lynch T; Mellick GD; Mutez E; Opala G; Park SS; Petrucci S; Quattrone A; Sharma M; Silburn PA; Sohn YH; Stefanis L; Tadic V; Tomiyama H; Uitti RJ; Valente EM; Vassilatis DK; Vilariño-Güell C; White LR; Wirdefeldt K; Wszolek ZK; Wu RM; Xiromerisiou G; Maraganore DM; Farrer MJ; Ross OA;
    Neurobiol Aging; 2014 Jan; 35(1):266.e5-14. PubMed ID: 23962496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case-control analysis of LRRK2 protective variants in Essential Tremor.
    Ng ASL; Ng EYL; Tan YJ; Prakash KM; Au WL; Tan LCS; Tan EK
    Sci Rep; 2018 Mar; 8(1):5346. PubMed ID: 29593234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leucine rich repeat kinase 2 (LRRK2) GLY2019SER mutation is absent in a second cohort of Nigerian Africans with Parkinson disease.
    Okubadejo NU; Rizig M; Ojo OO; Jonvik H; Oshinaike O; Brown E; Houlden H
    PLoS One; 2018; 13(12):e0207984. PubMed ID: 30507963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews.
    Thaler A; Ash E; Gan-Or Z; Orr-Urtreger A; Giladi N
    J Neural Transm (Vienna); 2009 Nov; 116(11):1473-82. PubMed ID: 19756366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The leucine rich repeat kinase 2 (LRRK2) G2019S substitution mutation. Association with Parkinson disease, malignant melanoma and prevalence in ethnic groups in Israel.
    Hassin-Baer S; Laitman Y; Azizi E; Molchadski I; Galore-Haskel G; Barak F; Cohen OS; Friedman E
    J Neurol; 2009 Mar; 256(3):483-7. PubMed ID: 19412725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNM3 and genetic modifiers of age of onset in LRRK2 Gly2019Ser parkinsonism: a genome-wide linkage and association study.
    Trinh J; Gustavsson EK; Vilariño-Güell C; Bortnick S; Latourelle J; McKenzie MB; Tu CS; Nosova E; Khinda J; Milnerwood A; Lesage S; Brice A; Tazir M; Aasly JO; Parkkinen L; Haytural H; Foroud T; Myers RH; Sassi SB; Hentati E; Nabli F; Farhat E; Amouri R; Hentati F; Farrer MJ
    Lancet Neurol; 2016 Nov; 15(12):1248-1256. PubMed ID: 27692902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses.
    Gustavsson EK; Follett J; Trinh J; Barodia SK; Real R; Liu Z; Grant-Peters M; Fox JD; Appel-Cresswell S; Stoessl AJ; Rajput A; Rajput AH; Auer R; Tilney R; Sturm M; Haack TB; Lesage S; Tesson C; Brice A; Vilariño-Güell C; Ryten M; Goldberg MS; West AB; Hu MT; Morris HR; Sharma M; Gan-Or Z; Samanci B; Lis P; Periñan MT; Amouri R; Ben Sassi S; Hentati F; ; Tonelli F; Alessi DR; Farrer MJ
    Lancet Neurol; 2024 Jun; 23(6):603-614. PubMed ID: 38614108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Motor and non-motor features of Parkinson's disease in LRRK2 G2019S carriers versus matched controls.
    Gunzler SA; Riley DE; Chen SG; Tatsuoka CM; Johnson WM; Mieyal JJ; Walter EM; Whitney CM; Feng IJ; Owusu-Dapaah H; Mittal SO; Wilson-Delfosse AL
    J Neurol Sci; 2018 May; 388():203-207. PubMed ID: 29627023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency of LRRK2 mutations in early- and late-onset Parkinson disease.
    Clark LN; Wang Y; Karlins E; Saito L; Mejia-Santana H; Harris J; Louis ED; Cote LJ; Andrews H; Fahn S; Waters C; Ford B; Frucht S; Ottman R; Marder K
    Neurology; 2006 Nov; 67(10):1786-91. PubMed ID: 17050822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease.
    Monfrini E; Di Fonzo A
    Adv Neurobiol; 2017; 14():3-30. PubMed ID: 28353276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of risk factor variants of LRRK2, MAPT, SNCA and TCEANC2 genes in Hungarian sporadic Parkinson's disease patients.
    Boros FA; Török R; Vágvölgyi-Sümegi E; Pesei ZG; Klivényi P; Vécsei L
    Neurosci Lett; 2019 Jul; 706():140-145. PubMed ID: 31085292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.